COPD trials recruiting in Texas

All COPD trials nationally

Cities in Texas

Recruiting trials in Texas

• A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
  NCT06283966 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female) · Texas: Abilene, Amarillo, Austin, Brownsville
• A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis
  NCT07725939 · Phase: Phase 2 · Ages: 40 Years to 80 Years · Sex: All (male and female) · Texas: Boerne
• A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)
  NCT07646587 · Phase: Phase 2 · Ages: 40 Years to 80 Years · Sex: All (male and female) · Texas: McKinney, Waxahachie
• A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
  NCT07053423 · Phase: Phase 4 · Ages: 40 Years to 85 Years · Sex: All (male and female) · Texas: Beaumont
• A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
  NCT07082738 · Phase: Phase 2 · Ages: 40 Years and older · Sex: All (male and female) · Texas: Boerne, Dallas, Denison, El Paso
• A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
  NCT06883305 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female) · Texas: Dallas, Forney, Fort Worth, Houston
• A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
  NCT06878261 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female) · Texas: Boerne, El Paso, Houston, Lewisville
• A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
  NCT07363694 · Phase: Phase 2, Phase 3 · Ages: 35 Years to 80 Years · Sex: All (male and female) · Texas: Boerne, Carrollton, Cypress, Dallas
• A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease
  NCT06603246 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Texas: Boerne
• An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema
  NCT06035120 · Phase: Not applicable (e.g. observational or device study) · Ages: 40 Years to 80 Years · Sex: All (male and female) · Texas: Dallas
• Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3
  NCT06891755 · Phase: Not applicable (e.g. observational or device study) · Ages: 40 Years to 84 Years · Sex: All (male and female) · Texas: Houston
• Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD
  NCT07059091 · Phase: Phase 2 · Ages: 40 Years and older · Sex: All (male and female) · Texas: Houston
• Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
  NCT06122077 · Phase: Not specified · Ages: 50 Years and older · Sex: All (male and female) · Texas: Houston, Tyler
• Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
  NCT05181826 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Texas: Dallas, Richardson
• Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
  NCT06959095 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female) · Texas: Corsicana
• Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
  NCT06961214 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female) · Texas: Austin, Dallas, El Paso, Houston
• Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
  NCT07190209 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female) · Texas: Beaumont, Bellaire, Boerne, Carrollton
• Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
  NCT07190222 · Phase: Phase 3 · Ages: 40 Years to 80 Years · Sex: All (male and female) · Texas: Dallas, Denison, El Paso, Houston
• Interprofessional Pharmacogenomics (IPGx) Registry and Repository
  NCT06726590 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Texas: Bryan
• STRIVE Post-Market Registry Study
  NCT04302272 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Texas: Dallas, Houston
• Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
  NCT07108166 · Phase: Not applicable (e.g. observational or device study) · Ages: 40 Years and older · Sex: All (male and female) · Texas: Denison, El Paso, Houston, Humble
• The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry
  NCT07612878 · Phase: Not specified · Ages: 40 Years and older · Sex: All (male and female) · Texas: North Richland Hills
• To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment
  NCT07684820 · Phase: Phase 2 · Ages: 40 Years to 85 Years · Sex: All (male and female) · Texas: Cypress, Tomball
• Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants With COPD
  NCT07610395 · Phase: Phase 2 · Ages: 40 Years to 85 Years · Sex: All (male and female) · Texas: Lewisville, Tomball
• eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
  NCT07177339 · Phase: Phase 3 · Ages: 40 Years to 75 Years · Sex: All (male and female) · Texas: Dallas, DeSoto, Greenville, Houston
• myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home
  NCT05204888 · Phase: Not applicable (e.g. observational or device study) · Ages: 30 Years and older · Sex: All (male and female) · Texas: Houston